Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal

publication date: Jan 9, 2024

Hong Kong’s Insilico Medicine sold global rights for its small molecule KAT6A inhibitor to Stemline Therapeutics, an oncology subsidiary of Italy’s Menarini Group, in a $500 million ($12 million upfront) agreement. Insilico, an AI drug discovery company, said the candidate targets hormone sensitive cancers and other oncology indications. Overexpression of KAT6A is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of the disease. In preclinical studies, the candidate showed inhibition against KAT6A in multiple CDX and PDX models with good efficacy and safety. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here